|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-2.12/-1.25
|
企業價值
122.76M
|
資產負債 |
每股賬面淨值
-0.82
|
現金流量 |
現金流量率
--
|
損益表 |
收益
8.57M
|
每股收益
0.04
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/17 00:30 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform). |